Related Experiment Video

Updated: May 26, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry

Mikael Ebbo1, Laurent Daniel, Michel Pavic

  • 1From Université de la Méditerranée Aix-Marseille II (ME, LD, SB, LC, JS, AB,NJ, B. Granel, JB, PJW, GK, JRH, NS), Marseille; Service de Médecine Interne (ME, LC, VV, KM, EB, GK, JRH, NS), Service de Néphrologie (SB, NJ), and Laboratoire d'Immunologie (JB), Hôpital de la Conception, AssistancePublique-Hôpitaux de Marseille, Marseille; Service d'Anatomie Pathologique et de Neuropathologie (LD), and Service de Médecine Interne (JS, AB,PJW), Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille; Service de Médecine Interne-Oncologie (MP), Hôpital D'instruction des Armées Desgenettes, Lyon; Service de Médecine Interne (PS), Hôtel-Dieu, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon; Service de Médecine Interne (MH), and Service de Rhumatologie (JMB), Hôtel Dieu, Centre Hospitalier Universitaire de Nantes, Nantes; Service de Médecine Interne(EA), Clinique Médicale B, Centre Hospitalier Universitaire de Strasbourg, Strasbourg; Inserm U897, Service de Médecine Interne et Tropicale (MLB), Hôpital Saint-André, Centre Hospitalier Universitaire de Bordeaux, Université Bordeaux 2 Victor-Segalen, Bordeaux; Service de Médecine Interne (MR), Hôtel Dieu, Centre Hospitalier Universitaire de Clermont-Ferrand; Service de Médecine Interne et Centre de Référence des Maladies auto-immunes et systémiques rares (JH), Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Université Paris 6, Paris; Service de Médecine Interne et Centre de référence des Cytopénies auto-immunes (B. Godeau), Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris 12, Créteil; Service de Médecine Interne (ABB), Centre Hospitalier Universitaire d'Angers, Angers; Service de Médecine Interne (TP), Hôpital Bichat-Claude Bernard, Assistance Publique- Hôpitaux de Paris, Université Paris 7, Paris; Service de Médecine Interne (JLP), Hôpital Robert Debré, Centre Hospitalier Universitaire de Reims, Reims; Service de Médecine Interne (CL, PR), and Service de Gastroentérologie(CS), Centre Hospitalier Universitaire la Miletrie, Poitiers; Service de Néphrologie (OM), Centre Hospitalier Universitaire de Nice, Nice; Service de Médecine Interne (B. Granel, FB), Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille; Service de Médecine Interne (HR), Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre Benite; Laboratoire Neurobiologie des Interactions Cellulaires et Neurophysiopathologie (NICN) (JB), CNRS UMR 6184, Faculté de Médecine, Université Aix-Marseille, Marseille; Service de Néphrologie (JJB), Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie, Paris; INSERM, UMR-S 938, Hôpital Saint-Antoine (PA), Université Pierre et Marie Curie, Paris; and Centre d'Immunologie de Marseille-Luminy (NS), Université de la Méditerranée, case 906, Campus de Luminy, Marseille, France.

Medicine
|December 27, 2011
PubMed

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...